# Oyster Therapeutics

**Source:** https://www.startuphub.ai/startups/oyster-therapeutics
**Profile type:** Startup

## About

Oyster Therapeutics is a London-based pharmaceutical company developing next-generation targeted protein degraders with an initial focus on tau-driven neurodegenerative diseases such as Alzheimer's. Its proprietary SELFTAC platform transforms large bifunctional degraders into small molecules via a reversible linker to enable oral bioavailability and CNS penetration. Its lead program is a small-molecule oral degrader designed to selectively clear pathological tau while preserving healthy tau, advanced in collaboration with Massachusetts General Hospital.

## Key facts

- **Slug:** oyster-therapeutics
- **Website:** https://oyster-tx.com
- **Location:** London, United Kingdom
- **Operating status:** Active
- **Total funding:** $98M
- **Sectors / tags:** Biotech, Drug Discovery, Therapeutics, Life Sciences, Pharmaceuticals
- **Social:**
  - LinkedIn: https://www.linkedin.com/in/harry-finch-9a67b83

## StartupHub.ai scores

- **Agent Readiness:** D (51/100)
- **Data Trust:** 76/100

## Funding rounds

| Date | Round | Amount | Lead investors |
| --- | --- | --- | --- |
| 10 Nov 2026 | [Series A](https://www.startuphub.ai/investment_rounds/oyster-therapeutics-series-a-2026) | $60M | - |
| 1 Jan 2023 | [Series A](https://www.startuphub.ai/investment_rounds/oyster-therapeutics-series-a-2023) | $6.3M | - |
| 1 Jan 2022 | [Series A](https://www.startuphub.ai/investment_rounds/oyster-therapeutics-series-a-2022) | $32M | - |

## Tech stack

Detected on oyster-tx.com, last scanned 2026-11-12.

- **Analytics:** Google Tag Manager
- **CMS / Builders:** Webflow
- **CDN:** Cloudflare
- **Email provider:** Microsoft 365

## JSON-LD

Structured data aligned with this page's `<script type="application/ld+json">` (included when the profile is server-rendered).

```json
{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://www.startuphub.ai"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Startups",
          "item": "https://www.startuphub.ai/startups"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Oyster Therapeutics",
          "item": "https://www.startuphub.ai/startups/oyster-therapeutics"
        }
      ]
    },
    {
      "@type": "ProfilePage",
      "@id": "https://www.startuphub.ai/startups/oyster-therapeutics#webpage",
      "url": "https://www.startuphub.ai/startups/oyster-therapeutics",
      "name": "Oyster Therapeutics - AI Startup Profile | StartupHub.ai",
      "description": "This is the StartupHub.ai profile of Oyster Therapeutics (formerly [\"Kesmalea Therapeutics\"]). Oyster Therapeutics is a startup operating in Biotech and Drug Discovery. Oyster Therapeutics is a London-based pharmaceutical company developing next-generation targeted protein degraders with an initial focus on tau-driven neurodegenerative diseases such as Alzheimer's. Headquartered in London, United Kingdom.",
      "dateModified": "2026-11-12T06:45:29.636Z",
      "mainEntity": {
        "@type": "Organization",
        "@id": "https://www.startuphub.ai/startups/oyster-therapeutics#organization"
      }
    },
    {
      "@type": "Organization",
      "@id": "https://www.startuphub.ai/startups/oyster-therapeutics#organization",
      "name": "Oyster Therapeutics",
      "url": "https://oyster-tx.com",
      "logo": "https://cdn.startuphub.ai/storage/v1/object/public/entity-images/logos/1704d5e5-f769-4115-87df-00921501fde8-square.webp",
      "image": "https://cdn.startuphub.ai/storage/v1/object/public/entity-images/logos/1704d5e5-f769-4115-87df-00921501fde8-square.webp",
      "description": "Oyster Therapeutics is a London-based pharmaceutical company developing next-generation targeted protein degraders with an initial focus on tau-driven neurodegenerative diseases such as Alzheimer's. Its proprietary SELFTAC platform transforms large bifunctional degraders into small molecules via a reversible linker to enable oral bioavailability and CNS penetration. Its lead program is a small-molecule oral degrader designed to selectively clear pathological tau while preserving healthy tau, advanced in collaboration with Massachusetts General Hospital.",
      "sameAs": [
        "https://www.linkedin.com/in/harry-finch-9a67b83"
      ],
      "address": {
        "@type": "PostalAddress",
        "addressLocality": "London",
        "addressCountry": "GB"
      },
      "knowsAbout": [
        "Biotech",
        "Drug Discovery",
        "Therapeutics",
        "Life Sciences",
        "Pharmaceuticals"
      ]
    }
  ]
}
```